DiviTum®TKa Research

Growing body of evidence

DiviTum has been studied widely in HR+ metastatic breast cancer, and also in other indications. The evidence demonstrates that measuring thymidine kinase activity levels with DiviTum provides important clinical data for the management of the disease.

To date, >10 publications support the application of DiviTum to potentially predicting and monitoring response to cell cycle regulating therapies: endocrine therapies, and CDK4/6 inhibitors.

The role of TK activity and the DiviTum®TKa test have been widely studied in breast cancer. Studies have shown the potential of the test as a monitoring tool and as a prognostic.

Serial evaluation of serum thymidine kinase activity is prognostic in women with newly diagnosed metastatic breast cancer

Read the full results from Larsson et al

TK is a dynamic marker of resistance to palbociclib which may lead to early identification of patients in whom treatment escalation may be feasible

Results from the TReND trial

Clinical validity of TKa as a prognostic marker in ER+/HER2- MBC patients treated with endocrine therapy and palbociclib

Results from a study at Institut Curie

Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor positive metastatic breast cancer

Results from analysis of the EFECT trial

Plasma thymidine kinase-1 activity predicts outcome in HR positive HER2 negative metastatic breast cancer treated with endocrine therapy

Results from the Prato Institute, Italy

Serum TK activity as a pharmacodynamic marker of CDK 4/6 inhibition in early-stage breast cancer patients receiving neoadjuvant palbociclib

Results from Washington University, St Louis

Selective CDK 4/6 inhibitors: Biologic Outcomes, Determinants of Sensitivity, Mechanisms of Resistance, Combinatorial Approaches, and Pharmacodynamic Biomarkers

ASCO 2020 Educational Book

Potential through simplicity: Thymidine Kinase–1 as a biomarker for CDK 4/6 inhibitors

British Journal of Cancer

Thymidine Kinase-1 as a biomarker in breast cancer: estimating prognosis and early recognition of treatment resistance

Biomarkers in Medicine

Serum Thymidine Kinase 1 Activity in the Prognosis and Monitoring of Chemotherapy in Lung Cancer Patients

Results from Hadassah and Hebrew University Medical Centre, Israel

Serum thymidine kinase 1 levels correlates with FDG uptake and prognosis in patients with non-small cell lung cancer

Results from Marmara University Hospital, Istanbul

Preoperative Serum Thymidine Kinase Activity as Novel Monitoring, Prognostic, and Predictive Biomarker in Pancreatic Cancer

Read more

Serum Thymidine Kinase 1 Activity Following Nephrectomy for Renal Cell Carcinoma and Radiofrequency Ablation of Metastases to Lung and Liver

Read more

Circulating Tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nefrectomy

Read more

Prognostic value of thymidine kinase activity in patients with chronic lymphocytic leukemia

Read more

Analysis of thymidine kinase serum levels by novel method DiviTum™ in multiple myeloma and monoclonal gammopathy of undetermined significance

Read more

High baseline serum thymidine kinase 1 level predicts unfavorable outcome in patients with follicular lymphoma

Read more

Identifying the stage of new CLL patients using TK, ZAP-70, CD38 levels

Read more